MARKET

BGNE

BGNE

Beigene Ltd
NASDAQ
162.54
-0.73
-0.45%
After Hours: 162.55 +0.01 +0.01% 19:12 07/26 EDT
OPEN
163.82
PREV CLOSE
163.27
HIGH
165.50
LOW
161.70
VOLUME
101.49K
TURNOVER
0
52 WEEK HIGH
225.23
52 WEEK LOW
126.97
MARKET CAP
16.99B
P/E (TTM)
-21.4753
1D
5D
1M
3M
1Y
5Y
1D
BeiGene (BGNE) Shares Cross Above 200 DMA
NASDAQ · 1d ago
Weekly Report: what happened at BGNE last week (0715-0719)?
Weekly Report · 4d ago
Executive reshuffles: Otis Worldwide, HSBC and Rockwell Automation in focus
Executive reshuffles: Otis Worldwide, HSBC and Rockwell Automation in focus. Several Wall Street executives stepped up for new roles as part of leadership reshuffling. Some companies added new positions to steer growth prospects such as Otis worldwide, HSBC, ROK and Glencore.
Seeking Alpha · 07/19 18:40
BeiGene Announces New CFO Appointment and Senior Advisor Transition
TipRanks · 07/18 10:58
BeiGene names Aaron Rosenberg as CFO
Healthcare BeiGene names Aaron Rosenberg as CFO. Rosenberg was most recently senior vice president and corporate treasurer of Merck from 2021. BeiGene, Ltd. Said it has appointed Aaron Rosenberg to the role effective July 22. Wang stepped down from the role to pursue external opportunities.
Seeking Alpha · 07/18 10:38
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
Aaron Rosenberg will succeed Julia Wang as Chief Financial Officer of BeiGene. Mr. Rosenberg is a global finance executive with more than 20 years of experience at Merck & Co. He was most recently Senior Vice President and Corporate Treasurer of Merck. BeiGene is a top 15 global oncology company.
Barchart · 07/18 05:30
Weekly Report: what happened at BGNE last week (0708-0712)?
Weekly Report · 07/15 09:04
With 47% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns
Institutional investors own 47% of BeiGene, Ltd. (NASDAQ:BGNE) The company is owned by institutions and the top 5% of the company have control of more than half of the business. The top 5 shareholders of Bei Gene have a stake in the company worth US$736m. High institutional ownership implies BeiGene's stock price is sensitive to their trading actions. The company's biggest shareholder is Amgen Inc., with a ownership of 18%. BeiGene is a good investment for those who want to see how the company will grow in the future. It's worth looking at the insider purchasing of shares in BeiGene.
Simply Wall St · 07/12 11:20
More
About BGNE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Webull offers Beigene Ltd (ADR) stock information, including NASDAQ: BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.